jcp quiz

Quizzes

Quiz

Quiz: Imaging Use Among Patients With Head and Neck Cancer

01/28/2022

True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.

True or False: Many patients...

01/28/2022

Journal of Clinical Pathways

Quiz

Quiz: Overall Survival in Patients With Prostate Cancer Receiving Enzalutamide or Abiraterone

01/27/2022

True or False: Prostate-specific antigen progression at 4 weeks after enzalutamide or abiraterone is associated with shorter overall survival

True or False: Prostate-specific...

01/27/2022

Journal of Clinical Pathways

Quiz

Quiz: Care Team Burden Impact on Treatment Selection for CLL

01/21/2022

True or False: Domain-specific appraisal of electronic communication portals hinders health care delivery and intervention and increases health care team burden.

True or False: Domain-specific...

01/21/2022

Journal of Clinical Pathways

Quiz

Quiz: Treatment Patterns for MCL

01/20/2022

True or False: Bendamustine plus rituximab is the most commonly used first-line treatment for MCL in the US, while receipt of stem cell transplant is uncommon.

True or False: Bendamustine plus...

01/20/2022

Journal of Clinical Pathways

Quiz

Quiz: Ibrutinib Safety for Relapsed/Refractory CLL

01/13/2022

True or False: Single-agent ibrutinib is safe and effective for relapsed/refractory CLL in routine practice.

True or False: Single-agent...

01/13/2022

Journal of Clinical Pathways

Sponsored

Quiz

Tumor Lysis Syndrome Risk in Patients Receiving Anticancer Therapies

01/06/2022

This engaging 5-question quiz explores risk of tumor lysis syndrome in patients receiving anticancer therapies.

This engaging 5-question quiz...

01/06/2022

Journal of Clinical Pathways

Quiz

Quiz: PARP Inhibitors in Patients With Epithelial Ovarian Cancer

12/14/2021

True or False: Findings from a study assessing patients’ and oncologists’ preferences for second-line PARP inhibitor maintenance in epithelial ovarian cancer suggest that the PFS gains are worth the toxicity risk.

True or False: Findings from a...

12/14/2021

Journal of Clinical Pathways

Quiz

Quiz: Differences Between Available PARP Inhibitors for Ovarian Cancer

12/08/2021

True or False: There are differences between available PARP inhibitors in the risk of experiencing a clinical event of interest, likelihood of dose modifications, ability to receive continuous therapy, health care resource utilization, and...

True or False: There are...

12/08/2021

Journal of Clinical Pathways

Quiz

Quiz: Consolidation and Maintenance vs Maintenance Alone for Newly Diagnosed MM

12/01/2021

True or False: Consolidation treatment with bortezomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance may improve progression-free survival and depth of response, compared to no consolidation in patients with newly...

True or False: Consolidation...

12/01/2021

Journal of Clinical Pathways

Quiz

Quiz: Cost-Effectiveness of Venetoclax Plus Obinutuzumab for CLL

11/22/2021

True or False: Fixed duration venetoclax plus obinutuzumab for 12 months is a cost-effective first-line treatment option for unfit patients with chronic lymphocytic leukemia.

True or False: Fixed duration...

11/22/2021

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Quizzes

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products